FindTrial
Sign In

MaaT013

DRUG5 trials

Sponsors

MaaT PHARMA, Assistance Publique Hopitaux De Paris, MaaT Pharma, Assistance Publique - Hôpitaux de Paris

Conditions

Acute Graft Versus Host Disease in IntestineMelanomaSteroid Refractory GVHDTreatment of acute graft-versus host disease (aGvHD) to the gastrointestinal (GI) tract of patients who are resistant or intolerant to ruxolitinib.

Phase 2

Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma
CompletedNCT04988841
Assistance Publique - Hôpitaux de ParisMelanoma
Start: 2022-01-20End: 2025-04-22Updated: 2025-08-28
PICASSO. Prospective randomIzed clinical trial assessing the tolerance and clinical benefit of feCAl tranSplantation in patientS with melanOma treated with CTLA-4 and PD-1 inhibitors
CompletedCTIS2024-516100-42-00
Assistance Publique Hopitaux De ParisMelanoma
Start: 2022-03-18End: 2025-04-22Target: 70Updated: 2025-07-10

Phase 3

MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients
Active, not recruitingNCT04769895
MaaT PharmaAcute Graft Versus Host Disease in Intestine, Steroid Refractory GVHD
Start: 2022-03-25End: 2025-11-30Updated: 2024-10-17
EvAluation of the efficacy of MaaT013 as salvage theRapy in acute GVHD patiEntS with gastrointestinal involvement, refractory to ruxolitinib; a multi-center open-label phase III trial.
CompletedCTIS2024-513023-17-00
MaaT PHARMATreatment of acute graft-versus host disease (aGvHD) to the gastrointestinal (GI) tract of patients who are resistant or intolerant to ruxolitinib.
Start: 2022-01-12End: 2025-09-24Target: 73Updated: 2025-02-24

Unknown Phase

Early Access Program With MaaT013 in Steroid-refractory Acute Gastrointestinal Graft Versus Host Disease
NCT04768907
MaaT PharmaAcute Graft Versus Host Disease in Intestine, Steroid Refractory GVHD
Updated: 2024-08-28

Related Papers

MaaT013 for ruxolitinib-refractory acute graft-versus-host disease with gastrointestinal involvement: Results from the ARES phase III trial
Blood2025-11-03
Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-<i>Versus</i>-Host Disease : Results from Early Access Program in Europe
Blood2024-11-051 citations
Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease : Results from Early Access Program in Europe
Blood2023-11-021 citations
Pooled allogeneic faecal microbiota MaaT013 for steroid-resistant gastrointestinal acute graft-versus-host disease: a single-arm, multicentre phase 2 trial.
2023-07-2627 citations